List of Excipients in Branded Drug FORTAMET

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Physicians Total Care Inc	FORTAMET	metformin hydrochloride	54868-5558	CANDELILLA WAX
Physicians Total Care Inc	FORTAMET	metformin hydrochloride	54868-5558	CELLULOSE ACETATE
Physicians Total Care Inc	FORTAMET	metformin hydrochloride	54868-5558	FERROSOFERRIC OXIDE
Physicians Total Care Inc	FORTAMET	metformin hydrochloride	54868-5558	HYPROMELLOSE

FORTAMET Excipient Strategy and Commercial Opportunities

Last updated: August 20, 2026

FORTAMET is an extended-release metformin hydrochloride tablet that uses an osmotic delivery system rather than a conventional hydrophilic matrix. Its commercial value comes from controlled metformin release, reduced dosing frequency, and improved gastrointestinal tolerability relative to immediate-release metformin for some patients. The main excipient opportunity is not a simple low-cost substitution. It is the development of equivalent osmotic, membrane-controlled, abuse-resistant, and low-cost platform technologies that avoid legacy formulation claims while preserving bioequivalence.

What is FORTAMET and how does its formulation work?

FORTAMET contains metformin hydrochloride in an extended-release osmotic tablet. The dosage strengths historically marketed in the United States include 500 mg, 750 mg, and 1,000 mg tablets. The product is indicated as an adjunct to diet and exercise for glycemic control in adults with type 2 diabetes mellitus.[1]

FORTAMET uses a multilayer tablet and semipermeable coating. The system generally includes:

1. A metformin-containing drug layer.
2. A polymeric push layer.
3. A semipermeable membrane.
4. A laser-drilled delivery orifice.
5. Excipients that regulate water uptake, swelling, osmotic pressure, tablet strength, and drug-layer processing.

The delivery system allows water to enter the tablet through the membrane. The push layer expands and forces the metformin drug layer through the precision orifice. The mechanism is materially different from a conventional matrix tablet, where drug diffuses through an eroding or swelling polymer network.

What excipients are associated with FORTAMET?

Public product information identifies excipient classes associated with the FORTAMET dosage form, including polymers, fillers, lubricants, binders, osmotic agents, and coating materials. Depending on strength and manufacturing configuration, relevant materials include:

Excipient function	Representative materials	Commercial role
Drug-layer binder	Povidone, hydroxypropyl cellulose or related binders	Granulation and mechanical strength
Drug-layer filler	Microcrystalline cellulose and related fillers	Tablet mass and manufacturability
Osmogen	Sodium chloride and other osmotic agents	Water uptake and osmotic pressure
Push-layer polymer	Polyethylene oxide or comparable high-molecular-weight polymer	Expansion and drug-layer displacement
Membrane former	Cellulose acetate or comparable semipermeable polymer	Controls water ingress
Lubricant	Magnesium stearate	Compression and ejection
Glidant	Colloidal silicon dioxide	Powder flow
Film coating	Hypromellose, polyethylene glycol, pigments or opacifiers	Identification, handling, and appearance

The precise commercial formulation should be established from the applicable FDA labeling, approved product records, and formulation development documentation. Excipient identity alone does not establish equivalence. Particle size, substitution level, molecular weight, viscosity grade, moisture content, coating weight, membrane permeability, and process history can materially affect release.

What excipient properties control FORTAMET performance?

The critical quality attributes are release rate, tablet integrity, membrane permeability, orifice performance, and resistance to dose dumping.

Polyethylene oxide and push-layer performance

High-molecular-weight polyethylene oxide is a central enabling material in osmotic systems. It must hydrate and expand consistently without excessive erosion or loss of mechanical strength. Key variables include:

• Molecular-weight distribution.
• Viscosity grade.
• Moisture content.
• Particle-size distribution.
• Compression force.
• Granulation method.
• Storage-induced crosslinking or hardening.

A lower-viscosity polymer can accelerate layer hydration and alter the release profile. A higher-viscosity grade can delay expansion and create incomplete delivery. Supplier changes therefore require more than standard excipient identity testing.

Cellulose acetate membrane control

The membrane controls water influx. Its performance depends on:

• Degree of acetyl substitution.
• Polymer molecular weight.
• Coating-solvent system.
• Membrane thickness.
• Coating uniformity.
• Plasticizer concentration.
• Drying temperature and residual solvent.

Small changes in coating porosity or thickness can produce significant changes in metformin release. Membrane coating is one of the strongest areas for process know-how and formulation differentiation.

Sodium chloride and osmotic pressure

Sodium chloride can increase osmotic pressure within the tablet and support a stable delivery rate. Its commercial advantages include low cost, global availability, and established regulatory familiarity. Risks include hygroscopicity, segregation, and sensitivity to particle size. Alternative osmotic agents may improve manufacturability but can require new bioequivalence and stability work.

Povidone, fillers, and lubricants

Povidone supports granulation and mechanical strength but can affect water uptake and drug-layer densification. Microcrystalline cellulose can improve compression but may change porosity. Magnesium stearate can reduce wetting when over-lubrication occurs, which can delay hydration and release.

For an osmotic formulation, these excipients are functional rather than inert. A supplier change involving a standard filler or lubricant can affect dissolution, tablet hardness, friability, and in vitro-in vivo correlation.

What patents protect the FORTAMET formulation?

FORTAMET originated from the Andrx osmotic drug-delivery platform and was commercialized through the metformin extended-release NDA pathway. Historical patent protection included U.S. patents directed to controlled-release metformin compositions and osmotic delivery systems. Publicly reported FORTAMET-related patent records include U.S. Patent Nos. 6,099,859 and 6,340,475, among other platform and formulation filings.[2][3]

Patent or patent family	General subject matter	Commercial relevance
U.S. 6,099,859	Controlled-release metformin delivery	Historical product and formulation protection
U.S. 6,340,475	Osmotic controlled-release metformin system	Relevant to tablet architecture and release control
Related platform filings	Osmotic membranes, push layers, and delivery systems	May affect design-around analysis

The principal branded-product patents are old and have reached or passed their listed expiration periods. Current commercial freedom to operate depends on the jurisdiction, continuation patents, formulation-specific claims, manufacturing patents, and the exact substitute formulation. A generic manufacturer can avoid an expired product patent while still facing risk from later patents directed to excipient grades, coating processes, manufacturing controls, or alternative delivery architectures.

When did FORTAMET lose exclusivity?

FORTAMET lost meaningful U.S. market exclusivity after expiration of its principal regulatory exclusivity and legacy formulation patents. FDA approval of generic metformin hydrochloride extended-release products created direct competition. Generic approvals have included both osmotic and non-osmotic extended-release formulations, depending on the product and approval pathway.[4]

The commercial exclusivity timeline is best separated into four categories:

Exclusivity category	FORTAMET position
NDA approval	Approved by FDA in 2004 under NDA 021574
Orphan exclusivity	Not applicable
New chemical entity exclusivity	Not applicable because metformin was previously approved
Formulation and patent exclusivity	Historical patents have expired or are no longer a major barrier to ordinary generic entry

The withdrawal of certain extended-release metformin products from the market because of N-nitrosodimethylamine contamination also affected supply and competitive positioning. FDA required recalls and manufacturer testing for affected lots, while products meeting applicable quality requirements remained eligible for marketing.[5]

What is the Orange Book status of FORTAMET?

FORTAMET is listed in FDA’s Orange Book as an approved prescription drug product associated with the metformin extended-release dosage form. Orange Book status should be reviewed by NDA number and current listing because patent listings, delistings, and approved manufacturers can change over time.[4]

The primary regulatory issues for a FORTAMET competitor are:

• Abbreviated New Drug Application eligibility.
• Reference-listed-drug selection.
• Product-specific bioequivalence.
• Comparative dissolution across multiple media and agitation conditions.
• Fed and fasting pharmacokinetics.
• Manufacturing consistency for a complex extended-release dosage form.
• Paragraph IV certification where a listed patent remains relevant.

Which companies have challenged FORTAMET?

Generic competition has come from companies developing metformin hydrochloride extended-release tablets, including manufacturers that marketed products under generic labels or alternative brands. Public litigation around extended-release metformin has included patent disputes involving controlled-release formulations and alleged infringement of osmotic delivery claims.

For a current transaction or launch assessment, the relevant question is not whether a historical FORTAMET patent was challenged. It is whether the proposed product infringes any unexpired patent listed for the reference product or any separate patent covering the proposed formulation, manufacturing method, or excipient system.

A Paragraph IV challenge can create a litigation-driven launch opportunity, but the value depends on:

• The number and scope of unexpired claims.
• Whether the claims cover the product or only a manufacturing step.
• The probability of a preliminary injunction.
• ANDA tentative-approval status.
• First-filer eligibility.
• The likelihood of a 180-day exclusivity period.
• Whether the patent owner has entered a settlement agreement.

What formulation patents remain commercially relevant?

Expired FORTAMET patents can still provide technical guidance without creating a current blocking position. The most commercially relevant patent opportunities now concern modified systems rather than direct duplication.

Potentially protectable formulation concepts

A developer could seek claims directed to:

• A lower-cost osmotic membrane with defined permeability.
• A high-load metformin tablet with reduced tablet size.
• A bilayer system using a non-polyethylene-oxide push layer.
• A membrane that reduces alcohol-induced release acceleration.
• A dosage form with improved gastrointestinal tolerability.
• A formulation compatible with automated coating equipment.
• A once-daily tablet with a controlled release profile across fed and fasting conditions.
• A moisture-stable formulation with reduced packaging requirements.
• A tablet architecture that reduces incomplete shell passage in stool.

Patent strength improves when claims combine composition, structure, process, and performance limitations. A claim limited only to common excipients such as sodium chloride, povidone, cellulose acetate, and polyethylene oxide is vulnerable to prior-art challenges. A claim tying those materials to defined viscosity, membrane permeability, coating weight, release parameters, and manufacturing steps is more defensible.

How strong is the FORTAMET patent estate?

The legacy patent estate has limited blocking strength because the main product and platform patents are old. Its technical influence remains substantial because the osmotic architecture is difficult to replicate reliably at commercial scale.

Factor	Assessment
Remaining basic composition protection	Low
Historical platform importance	High
Manufacturing know-how value	High
Generic formulation risk	Moderate
Barrier to simple immediate-release substitution	High
Barrier to conventional matrix alternatives	Moderate
Barrier to direct osmotic replication	Moderate to high
New patent opportunity	Moderate, if tied to measurable performance

The commercial moat is now more dependent on development know-how, regulatory execution, supply reliability, and manufacturing cost than on broad legacy patent claims.

What commercial opportunities exist for excipient suppliers?

Specialty polymer supply

Excipient suppliers can target high-molecular-weight polyethylene oxide, cellulose acetate, hypromellose, and functional coating polymers. The most valuable offering is not the raw material alone. It is a controlled, validated grade with documented:

• Molecular-weight distribution.
• Viscosity profile.
• Moisture limits.
• Particle-size profile.
• Residual-solvent performance.
• Lot-to-lot dissolution impact.
• Regulatory support package.

A supplier that can demonstrate equivalence across multiple batches can reduce formulation-change risk for generic developers.

Excipient co-processed systems

A co-processed osmotic excipient blend could combine a filler, osmogen, binder, and flow aid to simplify manufacturing. The product could be sold as a platform for high-dose extended-release tablets. The strongest commercial positioning would focus on reduced granulation steps, improved content uniformity, and consistent membrane performance.

Ready-to-coat membrane systems

Prequalified coating dispersions containing cellulose acetate, plasticizer, pore-forming agent, and pigment could reduce development time. A ready-to-use system with validated permeability ranges would have value for generic manufacturers and contract development and manufacturing organizations.

Alternative push-layer technologies

Polyethylene oxide is effective but can create supply, processing, and intellectual-property concerns. Alternatives include:

• Crosslinked hydrophilic polymers.
• Swellable cellulose derivatives.
• Superdisintegrant-based expansion systems.
• Layered systems using osmotically active polymer composites.
• Non-erosible elastomeric push layers.

These systems can support new patent filings if they produce a distinct release mechanism and reproducible pharmacokinetic profile.

How does FORTAMET compare with other metformin extended-release products?

Product type	Release mechanism	Excipient strategy	Development barrier	Commercial position
FORTAMET-type osmotic tablet	Membrane-controlled osmotic delivery	Functional membrane, osmogen, push layer	High	Differentiated once-daily profile
Conventional matrix metformin ER	Polymer swelling and diffusion	Hypromellose, fillers, lubricants	Moderate	Lower manufacturing cost
Generic osmotic metformin ER	Osmotic or equivalent controlled delivery	Similar functional excipients or design-around materials	Moderate to high	Direct reference-product competition
Immediate-release metformin	Rapid dissolution	Conventional tablet excipients	Low	Low-cost, multiple daily dosing
Modified-release multiparticulate product	Coated beads or granules	Functional coatings and carriers	Moderate	Flexible dose and release design

The lowest-cost competitor is usually a matrix formulation. The strongest direct substitute for FORTAMET is a product that matches the reference product’s pharmacokinetic profile while avoiding its historical patent claims.

What generic launch risks exist for FORTAMET?

Generic launch risks center on technical equivalence rather than basic active-ingredient availability.

Regulatory risks

FDA may scrutinize:

• Dose proportionality across strengths.
• Food effects.
• Incomplete tablet-shell passage.
• Release acceleration under alcohol exposure.
• Dissolution robustness.
• Batch-to-batch membrane variation.
• Differences between the test and reference product’s release mechanism.

Manufacturing risks

The main operational risks are:

• Uneven bilayer compression.
• Membrane defects.
• Variable laser-orifice diameter.
• Coating weight variation.
• Polymer hydration differences.
• Tablet cracking during packaging.
• Moisture-driven changes in release.
• Yield loss from complex coating and drilling steps.

IP risks

A developer must evaluate:

• Unexpired Orange Book patents.
• Continuations and divisionals.
• Process patents.
• Excipient-specific claims.
• Patents covering alcohol-resistant release.
• Patents on alternative osmotic systems.
• Settlement restrictions and launch dates.

What licensing deals could create value?

The most attractive licensing opportunities are likely to involve platform technology rather than the expired FORTAMET brand itself. Potential deal structures include:

1. A license to an osmotic delivery platform with freedom to operate in metformin and other high-dose drugs.
2. A supply agreement for validated polyethylene oxide or cellulose acetate grades.
3. A co-development agreement for a lower-cost FORTAMET-equivalent tablet.
4. A regional license covering markets where extended-release metformin penetration remains low.
5. A technology transfer agreement for coating, laser drilling, and bilayer compression.
6. A formulation license for a smaller tablet or alcohol-resistant metformin product.

Royalty value depends on whether the licensed technology reduces development time, improves approval probability, lowers manufacturing cost, or creates enforceable new patent claims.

What is the revenue opportunity for FORTAMET-related excipients?

Metformin is a large-volume, low-cost active ingredient. The value opportunity is therefore driven by scale and platform reuse rather than high unit pricing. A supplier can expand the addressable market by adapting the osmotic system to other high-dose, once-daily products, including selected cardiovascular, central nervous system, and gastrointestinal medicines.

Commercial value is highest in four segments:

Segment	Revenue driver
Functional polymer supply	Recurring high-volume excipient sales
Ready-to-use coating systems	Premium pricing and switching costs
CDMO formulation services	Development and manufacturing fees
Platform licensing	Royalties and milestone payments

A direct FORTAMET-equivalent product can face intense generic price competition. A validated excipient platform with multiple drug applications is more defensible.

Key Takeaways

• FORTAMET is a high-dose, once-daily metformin extended-release product based on an osmotic tablet system.
• Its formulation depends on functional excipients, especially membrane polymers, push-layer polymers, osmotic agents, binders, and coating materials.
• The main historical patents are old, and the legacy patent estate has limited current blocking strength.
• Manufacturing know-how remains valuable because membrane coating, bilayer compression, and laser-drilled delivery control are technically demanding.
• The strongest excipient opportunities involve validated polymer grades, ready-to-coat membrane systems, co-processed osmotic blends, and alternative push-layer technologies.
• Generic launch risk is concentrated in bioequivalence, dissolution robustness, food effects, alcohol sensitivity, and process reproducibility.
• New patent value is most likely to arise from measurable performance limitations tied to a defined excipient and manufacturing system.
• Licensing opportunities are stronger for reusable osmotic platforms than for the expired FORTAMET brand concept alone.

FAQs

Can a conventional hypromellose matrix tablet replace FORTAMET?

A conventional matrix tablet may provide extended release but does not automatically establish therapeutic or pharmacokinetic equivalence to an osmotic reference product. FDA requirements depend on the applicable product-specific guidance and reference-product characteristics.

Which excipient is most important in an osmotic metformin tablet?

No single excipient determines performance. The membrane polymer, push-layer polymer, osmogen, coating process, and delivery-orifice dimensions operate as an integrated system.

Is polyethylene oxide essential to FORTAMET?

Polyethylene oxide is a common push-layer material in osmotic systems, but alternative swellable polymers may be possible. Any substitution must preserve expansion, mechanical integrity, release rate, and bioequivalence.

Can an excipient supplier patent a FORTAMET substitute?

Yes. Patentable subject matter could include a defined excipient combination, polymer grade, membrane structure, manufacturing process, or release-performance profile. Common excipients without a novel functional relationship generally provide weaker protection.

Does FORTAMET have biosimilar risk?

No. Metformin is a small-molecule active ingredient. Competition occurs through generic drug pathways, including ANDAs, rather than biosimilar applications.

References

1. U.S. Food and Drug Administration. (2023). FORTAMET (metformin hydrochloride) extended-release tablets: Prescribing information. FDA/DailyMed.

2. U.S. Patent and Trademark Office. (2000). U.S. Patent No. 6,099,859: Controlled-release metformin formulations. USPTO Patent Center.

3. U.S. Patent and Trademark Office. (2002). U.S. Patent No. 6,340,475: Controlled-release metformin delivery systems. USPTO Patent Center.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

5. U.S. Food and Drug Administration. (2020). FDA updates and press announcements on metformin-containing products and NDMA testing. FDA.